Pancreatic Duodenal Homeobox Factor-1 (PDX-1) and Neurogenin-3 (NGN-3) in Gestational Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03964987|
Recruitment Status : Completed
First Posted : May 28, 2019
Last Update Posted : May 28, 2019
Introduction: Depletion of the ability of the cells ß to secrete the amount of insulin required by pregnancy, increasing the risk of develop Gestational Diabetes Mellitus (GDM). The aim was to contrast the messenger RNA (mRNA) expression of the pancreatic duodenal homeobox factor-1 (PDX-1) and Neurogenin-3 (Ngn-3) in peripheral blood of pregnant women with GDM versus women with normal pregnancies.
Material and methods: This was a prospective, clinical and cross-sectional study, conforming two groups of pregnant women: a) patients with a healthy gestation and b) patients with GDM. Besides anthropometry and routine laboratorial test, real-time polymerase chain reaction (Real-Time PCR), was used to quantify the expression of PDX-1 and NGN-3.
|Condition or disease|
Pregnant women attended in the Maternal-Fetal Medicine Service of the "Mónica Pretelini Sáenz" Maternal-Perinatal Hospital, were invited to participate. Those with autoimmune diseases, heart disease, nephropathy, liver disease or any other chronic condition were excluded and those with incomplete clinical files were discarded from the final analysis. Two groups were integrated: a) patients with a healthy gestation and b) patients with GDM.
From all patients the next information was captured in an excell sheet: weight, height, Body Mass Index, blood pressure, albumin, creatinine, electrolytes, glucose, total cholesterol, triglycerides, transaminases and relative expression of PDX-1 and NGN-3.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||48 participants|
|Target Follow-Up Duration:||9 Months|
|Official Title:||PDX-1 and NGN-3 Expression in Gestational Diabetes|
|Actual Study Start Date :||January 1, 2018|
|Actual Primary Completion Date :||August 30, 2018|
|Actual Study Completion Date :||December 31, 2018|
Women with normoevolutionary gestation.
Patients with GDM.
- ARNm expression [ Time Frame: Nine months ]Expression of the genes PDX-1 and NGN-3
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03964987
|Materno-Perinatal Hospital "Mónica Pretelini"|
|Toluca, Mexico, 50130|
|Principal Investigator:||Hugo Mendieta Zerón, PhD.||Maternal-Perinatal Hospital "Mónica Pretelini Sáenz"|